Company intelligence / Profile preview

Hessian Labs

Massachusetts, United Stateshessian-labs.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Hessian Labs has developed a proprietary non-invasive diagnostic tool based on platelet-sequestered proteomic panels ("HessMaps™") for early and accurate detection and monitoring of cancers. Their lead program targets prostate cancer, with future plans for other difficult-to-diagnose cancers. Clinical trials have been planned or initiated, but the test is not yet commercially available.

Therapeutic areas: Oncology
Modalities: Diagnostic assayProteomic panel (platelet sequestered proteins)
Industry: Protein Biomarker Diagnostics

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of now.

Beyond the preview

Go deeper on Hessian Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hessian Labs.

Explore the full profile